Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DSP-0390 + Atezolizumab as Maintenance Therapy for ES-SCLC
NCT07545954Phase 1Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Aug 2026
- Primary completion
- Sep 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of DSP-0390 in small cell lung cancer (SCLC) (3 arms), sponsored by Washington University School of Medicine. Primary endpoints: Incidence of treatment-emergent adverse events and Incidence of treatment-related adverse events. Started Aug 2026; status: recruiting.
02
Drugs
DSP-0390
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07545954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07545954.